Bacteriophages (phages) and other mobile genetic elements (MGEs) exert an immense selective pressure on     1    (bacterium), which in response have developed a broad arsenal of defence mechanisms.     2     these, CRISPR–Cas (clustered regularly interspaced short palindromic repeats–CRISPR-associated proteins) is a group of widespread RNA-guided adaptive immune systems that are classified into two broad classes, six types and numerous subtypes according to their genetic composition and interference mechanism1. The CRISPR–Cas immune response starts with the    3    (acquire) of short DNA fragments (protospacers) from invading MGEs. The protospacers are inserted as spacers between repeats in the CRISPR array to create a memory of the infection. Next, the CRISPR array is expressed    4     a long transcript that is processed into small, mature CRISPR RNAs (crRNAs), each    5    (carry) a spacer sequence flanked by part of the repeat. Finally, the interference complexes, composed     6     a crRNA and one (class 2) or more (class 1) Cas proteins, degrade the complementary nucleic-acid targets that are often found next to a short protospacer-adjacent motif (PAM). The specificity and programmability of the CRISPR–Cas machinery     7    (lead) to the development of various biotechnological applications in genome editing, molecular diagnostics and more.

In the evolutionary arms race with CRISPR–Cas, phages and other MGEs have evolved diverse strategies to block or circumvent immunity. One widespread evasion mechanism uses protein-    8    (base) CRISPR–Cas inhibitors called anti-CRISPRs (Acrs). So far, more than 100 Acr protein families have been identified    9     inhibit different stages of the CRISPR–Cas immune response, mainly by interacting directly with Cas proteins. For example, Acrs prevent crRNA loading, effector-complex formation, and target DNA binding and cleavage. Notably, the discovery of these natural ‘off switches’ has presented new opportunities    10    (control) the activity of CRISPR–Cas technologies.

9 . Bioengineering has the power to improve health globally by developing diagnostic (诊断法), treatment and disease monitoring platforms that function in diverse settings. This conference aims at improving the open exchange of ideas between bioengineers, clinical researchers, healthcare providers, funding and community partners, policymakers and educators, discussing the current impact of bioengineering on solving global health challenges and how to connect with communities.

This conference aims to provide a forum (论坛) to present research about:

► Improving for global health: low-cost diagnostics

► Establishing effective treatment

► Funding and publishing global health-related bioengineering research

► Providing training and education as a means to advance global health

► Capacity building for disease prevention

Submission Deadline September 8, 2023

PLEASE NOTE: You must register for the conference in order to be accepted.

How to submit:

1. Click “Submit Abstract”

2. Create an account, follow the steps and submit your research

3. Register for the conference

4. Check your email for a decision email

You will be informed via email shortly after the deadline whether you have been accepted or not.

* Submission confirmation and future communications will come from a natuteconferences@nature.com email address.

Fee:

10 . Personalized medicine changes conventional medicine which typically offers blanket recommendations and offers treatments designed to help more people than they bam but that might not work for you. The approach recognizes that we each possess unique characteristics, and they have an out size impact on our health.

Around the world, researchers are creating precision tools unimaginable just a decade ago: superfast DNA sequencing(排序); tissue engineering, cell reprogramming, gene editing, and more. The science and technology soon will make it possible to predict your risk of cancer, heart disease, and countless other illnesses years before you get sick. The work also offers prospects for changing genes in removing some diseases.

Last spring, researchers at the National Cancer Institute reported the dramatic recovery of a woman with breast cancer, Judy Perkins. The team, led by Steven Rosenberg, an immune(免疫的) treatment pioneer, had sequenced her cancer cells’ DNA to analyze the sudden change. The team also removed a sampling of immune cells and tested them to see which ones recognized her cancer cells' genetic faults. The scientists reproduced the winning immune cells by the billions and put them into Perkins to attack her cancer cells. More than two y cars later. Perkins, a retired engineer from Florida, shows no signs of cancer.

Thirty years ago, scientists thought that it would be impossible to understand our genetic rules and sequence the 3.2 billion pairs of different elements in our DNA. “It was like you were talking fairytales,” Kurzrock said. “The conventional wisdom was that it would never happen. Never And then in 2003, never was over.”

It took the Human Gene Project 13 years, roughly one billion dollars, and scientists from six countries to sequence one gene complex. Today sequencing costs about a thousand dollars. The latest machines can produce the results in a day. The technology, combined with advanced cell analysis, clarifies the astonishing biochemical variations that make every human body unique.